330 related articles for article (PubMed ID: 33355184)
1. BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.
Alpsoy A; Utturkar SM; Carter BC; Dhiman A; Torregrosa-Allen SE; Currie MP; Elzey BD; Dykhuizen EC
Cancer Res; 2021 Feb; 81(4):820-833. PubMed ID: 33355184
[TBL] [Abstract][Full Text] [Related]
2. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.
Alpsoy A; Dykhuizen EC
J Biol Chem; 2018 Mar; 293(11):3892-3903. PubMed ID: 29374058
[TBL] [Abstract][Full Text] [Related]
3. A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells.
Gatchalian J; Malik S; Ho J; Lee DS; Kelso TWR; Shokhirev MN; Dixon JR; Hargreaves DC
Nat Commun; 2018 Dec; 9(1):5139. PubMed ID: 30510198
[TBL] [Abstract][Full Text] [Related]
4. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity.
Link KA; Balasubramaniam S; Sharma A; Comstock CE; Godoy-Tundidor S; Powers N; Cao KH; Haelens A; Claessens F; Revelo MP; Knudsen KE
Cancer Res; 2008 Jun; 68(12):4551-8. PubMed ID: 18559499
[TBL] [Abstract][Full Text] [Related]
5. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.
Michel BC; D'Avino AR; Cassel SH; Mashtalir N; McKenzie ZM; McBride MJ; Valencia AM; Zhou Q; Bocker M; Soares LMM; Pan J; Remillard DI; Lareau CA; Zullow HJ; Fortoul N; Gray NS; Bradner JE; Chan HM; Kadoch C
Nat Cell Biol; 2018 Dec; 20(12):1410-1420. PubMed ID: 30397315
[TBL] [Abstract][Full Text] [Related]
6. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
7. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
8. Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer.
Yu J; Zhou P; Du W; Xu R; Yan G; Deng Y; Li X; Chen Y
Biochem Pharmacol; 2020 Jul; 177():113946. PubMed ID: 32247852
[TBL] [Abstract][Full Text] [Related]
9. Differential Modulation of Polycomb-Associated Histone Marks by cBAF, pBAF, and gBAF Complexes.
Bergwell M; Park J; Kirkland JG
bioRxiv; 2024 Jan; ():. PubMed ID: 37790495
[TBL] [Abstract][Full Text] [Related]
10. BRD9 determines the cell fate of hematopoietic stem cells by regulating chromatin state.
Xiao M; Kondo S; Nomura M; Kato S; Nishimura K; Zang W; Zhang Y; Akashi T; Viny A; Shigehiro T; Ikawa T; Yamazaki H; Fukumoto M; Tanaka A; Hayashi Y; Koike Y; Aoyama Y; Ito H; Nishikawa H; Kitamura T; Kanai A; Yokoyama A; Fujiwara T; Goyama S; Noguchi H; Lee SC; Toyoda A; Hinohara K; Abdel-Wahab O; Inoue D
Nat Commun; 2023 Dec; 14(1):8372. PubMed ID: 38102116
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Value of
Barma N; Stone TC; Carmona Echeverria LM; Heavey S
Biomolecules; 2021 Nov; 11(12):. PubMed ID: 34944438
[TBL] [Abstract][Full Text] [Related]
13. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
[TBL] [Abstract][Full Text] [Related]
14. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
Nguyen VT; Tessema M; Weissman BE
Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
[TBL] [Abstract][Full Text] [Related]
15. Differential requirements for different subfamilies of the mammalian SWI/SNF chromatin remodeling enzymes in myoblast cell cycle progression and expression of the Pax7 regulator.
Padilla-Benavides T; Olea-Flores M; Nshanji Y; Maung MT; Syed SA; Imbalzano AN
Biochim Biophys Acta Gene Regul Mech; 2022 Feb; 1865(2):194801. PubMed ID: 35217218
[TBL] [Abstract][Full Text] [Related]
16. A Genome-wide CRISPR Screen Reveals a Role for the Non-canonical Nucleosome-Remodeling BAF Complex in Foxp3 Expression and Regulatory T Cell Function.
Loo CS; Gatchalian J; Liang Y; Leblanc M; Xie M; Ho J; Venkatraghavan B; Hargreaves DC; Zheng Y
Immunity; 2020 Jul; 53(1):143-157.e8. PubMed ID: 32640256
[TBL] [Abstract][Full Text] [Related]
17. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis.
Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C
Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722
[TBL] [Abstract][Full Text] [Related]
18. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
19. SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes.
Middeljans E; Wan X; Jansen PW; Sharma V; Stunnenberg HG; Logie C
PLoS One; 2012; 7(3):e33834. PubMed ID: 22442726
[TBL] [Abstract][Full Text] [Related]
20. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.
Asangani IA; Wilder-Romans K; Dommeti VL; Krishnamurthy PM; Apel IJ; Escara-Wilke J; Plymate SR; Navone NM; Wang S; Feng FY; Chinnaiyan AM
Mol Cancer Res; 2016 Apr; 14(4):324-31. PubMed ID: 26792867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
